Kisqali Drug Interactions: 401 Major, 443 Moderate
Kisqali (Ribociclib) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Kisqali. Always confirm against the full prescribing information.
100 interactions
Abacavir
Abacavir may increase the hepatotoxic activities of Ribociclib.
Level 2 evidence
Abemaciclib
The metabolism of Abemaciclib can be decreased when combined with Ribociclib.
Level 1 evidence
Acalabrutinib
The serum concentration of Acalabrutinib can be increased when it is combined with Ribociclib.
Level 1 evidence
Acarbose
Acarbose may increase the hepatotoxic activities of Ribociclib.
Level 2 evidence
Acebutolol
The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Acebutolol.
Level 1 evidence
Acenocoumarol
The serum concentration of Acenocoumarol can be increased when it is combined with Ribociclib.
Level 1 evidence
Acitretin
Acitretin may increase the hepatotoxic activities of Ribociclib.
Level 2 evidence
Acrivastine
The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Acrivastine.
Level 1 evidence
Adagrasib
The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Adagrasib.
Level 1 evidence
Adenosine
The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Adenosine.
Level 1 evidence
Albuterol
The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Albuterol.
Level 1 evidence
Alcaftadine
The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Alcaftadine.
Level 1 evidence
Enter your NPI to unlock 34 major interactions for Kisqali
Kisqali (Ribociclib) has 1009 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Kisqali (Ribociclib) has 401 major, 443 moderate, and 165 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Kisqali. Always confirm against the full prescribing information.